Ten-year mortality, disease progression, and treatment-related side effects in men with localized prostate cancer from the ProtecT randomized controlled trial according to treatment received

European Urology Dec 04, 2019

Neal DE, Metcalfe C, Donovan JL, et al. - Men with clinically localized prostate cancer at one of nine UK centers were invited to take part in a treatment trial comparing active monitoring (AM), radical prostatectomy, and radiotherapy in order to assess outcomes according to treatment. Analyses according to treatment received revealed raised rates of disease-related events and cheaper rates of patient-reported harms in men managed by AM in comparison with men managed by radical treatment, and more substantial proof of more comprehensive prostate cancer mortality in the AM group.

Full text available Go to Original

Sign-up to continue reading. It is free & takes less than 2 mins

  • 45 lakhs+ doctors trust M3 globally

  • Nonloggedininfinity icon
    Free & unlimited access to original articles and quizzes
  • Nonloggedinlock icon
    Secure: we never sell your data
This article is only available to members. Are you a doctor? Click here to signup for free.
Try M3 India / Log In
M3 app logo
Choose easy access to M3 India from your mobile!

M3 instruc arrow
Add M3 India to your Home screen
Tap  Chrome menu  and select "Add to Home screen" to pin the M3 India App to your Home screen